Open AccessPhase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Author(s) -
Ahmad A. Tarhini,
Sandra J. Lee,
F. Stephen Hodi,
Uma Rao,
Gary I. Cohen,
Omid Hamid,
Laura F. Hutchins,
Jeffrey A. Sosman,
H. Kluger,
Zeynep Eroglu,
Henry Koon,
Donald P. Lawrence,
Kari Kendra,
David R. Minor,
Carrie B. Lee,
Mark R. Albertini,
Lawrence E. Flaherty,
Teresa M. Petrella,
Howard Streicher,
Ver K. Sondak,
John M. Kirkwood
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.01381
Subject(s) - medicine , ipilimumab , discontinuation , adverse effect , hazard ratio , melanoma , adjuvant , cancer , gastroenterology , phases of clinical research , oncology , clinical trial , surgery , confidence interval , immunotherapy , cancer research
Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10). E1609 evaluated the safety and efficacy of ipilimumab at 3 mg/kg (ipi3) and ipi10 versus HDI.